Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes
- 17 December 2015
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 46 (1), 70-79
- https://doi.org/10.1111/eci.12570
Abstract
[[abstract]]BACKGROUND: The risk of pancreatic cancer associated with incretin-based therapies is controversial. METHODS: This study retrospectively analyzed the National Health Insurance database including patients with newly diagnosed type 2 diabetes mellitus at an age >/=25 years between 1999 and 2010. A total of 71,137 ever users of sitagliptin and 933,046 never users were followed for pancreatic cancer until December 31, 2011. A time-dependent approach was used to calculate incidence and estimate hazard ratios adjusted for propensity score using Cox regression. RESULTS: During follow-up, 83 ever users and 3,658 never users developed pancreatic cancer, representing an incidence of 73.6 and 55.0 per 100,000 person-years, respectively. The adjusted hazard ratio (95% confidence intervals) for ever versus never users was 1.40 (1.13-1.75). The respective adjusted hazard ratio for the first, second, and third tertile of cumulative dose 33,700 mg was 1.83 (1.28-2.62), 1.97 (1.41-2.76) and 0.72 (0.45-1.15). For average daily dose of /=100 mg, the respective hazard ratio was 3.10 (1.17-8.26), 1.01 (0.63-1.61) and 1.53 (1.18-1.97). CONCLUSIONS: Sitagliptin is significantly associated with a higher risk of pancreatic cancer, especially when the cumulative dose is <33,700 mg. The risk diminished in users with a higher cumulative dose. The daily dose of sitagliptin should better be kept <100 mg and its use should be reconsidered in patients who suffer from severe renal impairment and thus a daily dose of <50 mg is always recommended. Future studies are required to confirm the findings with more appropriate adjustment for smokingKeywords
Funding Information
- Ministry of Science and Technology, Taiwan (103-2314-B-002-187-MY3)
This publication has 21 references indexed in Scilit:
- An Updated Review on Cancer Risk Associated with Incretin Mimetics and EnhancersJournal of Environmental Science and Health, Part C, 2015
- Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort studyDiabetes, Obesity and Metabolism, 2014
- A Review on Thiazolidinediones and Bladder Cancer in Human StudiesJournal of Environmental Science and Health, Part C, 2014
- Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetesAnnals of Medicine, 2013
- A Critical Analysis of the Clinical Use of Incretin-Based TherapiesDiabetes Care, 2013
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical StudiesDiabetes Therapy, 2013
- Pioglitazone and Bladder CancerDiabetes Care, 2012
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trialsCurrent Medical Research and Opinion, 2011
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Evaluating Medication Effects Outside of Clinical Trials: New-User DesignsAmerican Journal of Epidemiology, 2003